Further, potassium IK1/SK4/KCa3.1 channels are also under intense investigation because of their high potential in therapeutic drug development for various pathophysiological conditions, including sickle cell anemia, pancreatic cancer, arterial restenosis, immune diseases, and CNS inflammation (Jensen et al., 2002; Köhler et al., 2003; Wulff et al., 2003; Jager et al., 2004). Here, KCNN4 is linked to sickle cell disease.